Geron (GERN) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Geron (NASDAQ:GERN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Do insiders & institutionals have more ownership in FOLD or GERN?

73.7% of Geron shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by insiders. Comparatively, 3.1% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, FOLD or GERN?

Amicus Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Does the media favor FOLD or GERN?

In the previous week, Geron had 31 more articles in the media than Amicus Therapeutics. MarketBeat recorded 38 mentions for Geron and 7 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.06 beat Geron's score of 0.10 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Geron	4 Very Positive mention(s)	1 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is FOLD or GERN more profitable?

Amicus Therapeutics has a net margin of -10.62% compared to Geron's net margin of -682.48%. Amicus Therapeutics' return on equity of 12.44% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-10.62%	12.44%	2.60%
Geron	-682.48%	-67.53%	-45.46%

Which has stronger valuation & earnings, FOLD or GERN?

Amicus Therapeutics has higher revenue and earnings than Geron. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$528.30M	5.00	-$151.58M	-$0.18	-47.72
Geron	$76.99M	13.65	-$184.13M	-$0.27	-6.11

Do analysts prefer FOLD or GERN?

Amicus Therapeutics currently has a consensus target price of $16.75, suggesting a potential upside of 94.99%. Geron has a consensus target price of $5.75, suggesting a potential upside of 248.48%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Geron	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82

Does the MarketBeat Community believe in FOLD or GERN?

Amicus Therapeutics received 32 more outperform votes than Geron when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 70.03% of users gave Geron an outperform vote.

Company	Underperform	Outperform
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%
Geron	Outperform Votes 500 70.03%	Underperform Votes 214 29.97%

Summary

Amicus Therapeutics beats Geron on 10 of the 18 factors compared between the two stocks.